Loading clinical trials...
Loading clinical trials...
A Phase 3, Long-Term, Open-Label Safety Study of LY2951742 in Patients With Migraine
The main purpose of this study is to evaluate the longer term safety of the study drug known as galcanezumab in participants with episodic or chronic migraine.
Age
18 - 65 years
Sex
ALL
Healthy Volunteers
No
California Medical Clinic for Headache
Santa Monica, California, United States
Encompass Clinical Research
Spring Valley, California, United States
New England Institute for Clinical Research
Stamford, Connecticut, United States
Sunrise Clinical Research
Hollywood, Florida, United States
Jacksonville Center for Clinical Research
Jacksonville, Florida, United States
Mercy Health Research
St Louis, Missouri, United States
Albuquerque Neurosciences
Albuquerque, New Mexico, United States
PharmQuest
Greensboro, North Carolina, United States
Wilmington Health Associates
Wilmington, North Carolina, United States
Suburban Research Associates
Media, Pennsylvania, United States
Start Date
November 30, 2015
Primary Completion Date
May 12, 2017
Completion Date
August 14, 2018
Last Updated
June 17, 2020
270
ACTUAL participants
Galcanezumab
DRUG
Lead Sponsor
Eli Lilly and Company
NCT06641466
NCT07018713
NCT04715685
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions